Foreword xvii
Foreword xix
Preface xxi
Acknowledgments xxvii
1 Pharmaceutical Dissolution Testing: Fundamentals and Essential Applications (An Overview) 1
1.1 Introduction and Objective(s) 1
1.2 Science of Dissolution Over Past 120+ Years 3
1.2.1 Journey from Quality Control (QC) to Development 5
1.3 Fundamentals of Dissolution Testing (An Overview) 6
1.4 Factors Influencing Dissolution Test(ing) 8
1.5 Pharmaceutical Product Life Cycle: Role of Dissolution (An Overview) 12
1.6 Dissolution Test(ing): What It Is and What It Is Not! 13
1.7 Need for This Textbook 14
1.8 Summary and Concluding Remarks 15
References 16
2 Bioavailability (BA) and Bioequivalence (BE): Fundamentals and Applications in Drug Product Development 20
2.1 Introduction and Objective(s) 20
2.2 Definitions 21
2.3 Bioequivalence (BE) Testing: Basics, Advances, and Global Perspectives 23
2.3.1 BA/BE Study Designs 26
2.3.2 Sample Size, n 28
2.3.3 BE (Acceptance) Criteria and Statistical Considerations 31
2.3.4 Bioequivalence (BE) Studies: Role of Modeling and Simulations 33
2.3.5 Surrogates to BE 35
2.3.6 PD Endpoint-Based and Clinical Endpoint-Based BE Assessment 37
2.3.7 Regulatory Requirements 40
2.4 Current Challenges and Solutions (Insight into Chapter 14) 43
2.5 Summary and Concluding Remarks 44
References 44
3 Solubility, Dissolution, Permeability, and Classification Systems 54
3.1 Introduction and Objective(s) 54
3.2 Definitions 56
3.3 Solubility Versus Solubilization: What Is Critical in Development? 58
3.3.1 Theories of Solubilization 58
3.3.2 Solubility: Challenges in Drug Development! 63
3.3.3 Solubility Enhancement: Purpose, Theoretical and Practical Considerations! 68
3.4 Dissolution: Intrinsic Versus Apparent! 70
3.4.1 Theories of Dissolution 70
3.4.1.1 Noyesâ"Whitney Theory (1897) 70
3.4.1.2 Brunner and Tolloczko Theory (1900) 71
3.4.1.3 Nernst and Brunner Theory (1904) 71
3.4.2 Intrinsic Versus Apparent Dissolution 72
3.5 Permeability Versus Permeation (Process): What Is Critical for Bioefficacy! 74
3.6 Classification Systems: Theoretical Versus Pragmatic Considerations! 75
3.7 Summary and Concluding Remarks 78
References 79
4 Understanding the Mechanics of Dissolution: Mathematical Models and Simulations 86
4.1 Introduction and Objective(s) 86
4.2 Mechanics of Dissolution: Theories, Presumptions, and Reality Check 87
4.3 Dissolution Theories/Models 91
4.4 Dissolution Mechanics (Model-Dependent Methods) 92
4.4.1 Zero Order 92
4.4.2 First-Order Model (Gibaldiâ"Feldman Model 1967) 93
4.4.3 Makoidâ"Banakar Model (1993) 93
4.4.4 Hixson and Crowell Model (1931) 95
4.4.5 Higuchi Model (1961, 1963, 1967) 96
4.4.6 Bakerâ"Lonsdale (1974) 97
4.4.7 Korsmeyerâ"Peppas Model (1983) 98
4.4.8 Hopfenberg Model (1976) 98
4.4.9 Gompertz Distribution Model 99
4.4.10 El-Yazigi Model (1981) 100
4.5 Dissolution Mechanics (Model-Independent Methods) 101
4.5.1 Weibull Distribution Model (1951) 101
4.5.2 Statistical Mean Time Concept/Model (1982) 101
4.5.3 (Other) Statistical Regression-Based Models 102
4.5.4 Sequential Model 102
4.5.5 Density Function Theory (DFT) 103
4.6 Relevance of Mathematical Modeling of Dissolution 104
4.7 Purposeful Modeling and Simulation 105
4.8 Summary and Concluding Remarks 106
References 107
5 Dissolution Testing Methods: Necessity Is the Mother of Invention! 110
5.1 Introduction and Objective(s) 110
5.2 Need for Dissolution Testing Method 112
5.3 Dissolution Testing Methods 113
5.3.1 Science of Dissolution 114
5.3.2 Intrinsic and Apparent Dissolution Methods 116
5.3.3 Compendial Methods Versus Regulatory Perspective 120
5.3.4 Predictive Testing Methods and âBiorelevant Dissolutionâ Methods 124
5.4 Necessity Is the Mother of Invention! 137
5.4.1 Controlled Release Parenteral Systems Including Drug-Eluting Stents 138
5.4.2 Pharmaceutical Formulations for the Oral Cavity 139
5.4.2.1 Soft Gelatin Capsules (SGC): Oral Delivery and Rectal Inserts 144
5.4.3 Inhalation Products 145
5.4.4 Semisolid Pharmaceutical Systems Including Transdermal Drug Delivery Systems (TDDSs) 148
5.4.5 Nanotechnology-Based Systems: Nanobiomedicine Formulations 149
5.4.6 Others 150
5.5 The Perpetual Struggle 152
5.6 Concluding Remarks 154
References 155
6 Essentials of Dissolution Testing of Pharmaceutical Systems 166
6.1 Introduction and Objective(s) 166
6.2 Objectives of Dissolution Testing of Pharmaceutical Systems 167
6.3 Oral Solid Dosage Forms (SDFs) 168
6.3.1 Immediate Release/Rapid Release SDFs 170
6.3.1.1 Conventional IR SDFs (Focus: Recent Advances in Solubility Enhancement!) 171
6.3.1.2 Chewable: Tablets and Gums 175
6.3.2 Modified Release (MR) SDFs 179
6.3.3 Advanced/Innovative MR-SDFs 193
6.4 Oral Liquid Dosage Forms 197
6.4.1 Rapid Release Systems (RRSs) 198
6.5 Non-oral Dosage Forms 201
6.5.1 Topical Dosage Forms 202
6.5.1.1 Traditional Topical Dosage Forms 203
6.5.1.2 Transdermal Drug Delivery Systems 204
6.5.1.3 Nasal, Ocular, Otic, Vaginal, and Rectal Dosage Forms 205
6.5.2 Parenteral Dosage Forms 213
6.6 Nanotechnology-Based Pharmaceutical Systems 220
6.7 Nutraceuticals and Natural Products 221
6.8 Concluding Remarks: Need for Purposeful Dissolution/Release Testing! 225
References 226
7 Dissolution/Release Test Data (Profile): Requirements, Analyses, and Regulatory Expectations 237
7.1 Introduction and Objective(s) 237
7.2 Academic Curiosity 239
7.3 Early Development 241
7.4 Product Development Stage 242
7.5 Comparative Analyses 244
7.6 Summary and Concluding Remarks 248
References 250
8 Automation in Dissolution Testing: Recent Advances and Continuing Challenges! 254
8.1 Introduction and Objective(s) 254
8.2 Automated Dissolution Testing: Why and What to Automate? 255
8.3 Challenges in Automation of Dissolution Test(ing) 263
8.4 Automation in Dissolution Testing: Looking Forward! 264
8.5 Concluding Remarks 266
References 267
9 In vitroâ"In vivo Correlations (IVIVCs): What Makes Them Challenging! 269
9.1 Introduction and Objective(S) 269
9.2 Basic Model, Scheme, and Assumptions 270
9.3 Mechanics for Determination of IVIVC 277
9.4 BCS and IVIVC 280
9.5 IVIVC in New Drug Development vis- -vis Generic Drug Development 283
9.6 IVIVCs in Topical/Transdermal Drug Delivery Systems (TDDSs) 284
9.7 Nonlinear IVIVCs 286
9.8 Validation of IVIVC Prediction Error (PE) 286
9.9 IVIVC in Drug Product Life Cycle: What Is the Ultimate Objective? 287
9.10 Summary and Conclusions 289
References 289
10 Biorelevant Dissolution/Release Test Method Development for Pharmaceutical Dosage Forms 294
10.1 Introduction and Objective(s) 294
10.2 General Considerations in BDM Development 295
10.3 Oral Drug Delivery Systems 296
10.3.1 Challenges in the Simulation of GI Biorelevant Factors: Motility and Hydrodynamics 299
10.3.2 Biorelevant Dissolution Media for Oral Drug Delivery Systems 301
10.4 Inhalation Drug Delivery Systems 303
10.5 Parenteral Drug Delivery Systems 306
10.6 Other Drug Delivery Systems 308
10.7 The Roadmap 309
10.8 Summary and Concluding Remarks 310
References 311
11 Bioavailability Prediction Software: Hype or Reality! 320
11.1 Introduction and Objective(s) 320
11.2 The Need for Simulations and Predictions in Drug Product Development 322
11.3 Simulation and Prediction of In Vivo Performance: The Catch- 22 Situation!325
11.4 Bioavailability (BA)/Bioequivalence (BE) Simulation Software: What They Do and Do Not! 327
11.5 Appreciating and Depreciating Potential Utility of BA Prediction Software 335
11.6 Concluding Remarks 336
References 337
12 Challenges and Unique Applications of IVIVC in Drug Development 340
12.1 Introduction and Objective(s) 340
12.2 USP <1088> and US FDA Guidance for Industry (1997): Operational Challenges 342
12.3 Applications of IVIVC(s) 347
12.4 Prospective IVIVC(s) 349
12.4.1 Background 349
12.4.2 Process 349
12.4.3 Application 352
12.4.3.1 Unique Application of IVIVC 353
12.5 Retrospective IVIVC(s): Responding to Agency Queries! 355
12.6 Summary and Concluding Remarks 361
References 362
13 Dissolution Testing in Generic Drug Development: Methods, Requirements, and Regulatory Expectations/Requirements 366
13.1 Introduction and Objective(s) 366
13.2 Generic Drug Development Process: Role of Dissolution Testing 368
13.2.1 Preformulation 369
13.2.2 Prototype Formulation 371
13.2.3 Prospective Development: IVIVC with BE as the Objective! 372
13.2.4 Pilot BE to Pivotal BE 375
13.3 Generic Pharmaceutical Systems: Role of Dissolution 375
13.3.1 Traditional: Para III Formulations â" Rush to âFirst to Fileâ 376
13.3.2 Para IV Formulations 377
13.3.3 Exploring 505(b)(2) Opportunities 380
13.3.4 Differentiated Products and/or Incremental Innovations 384
13.3.5 Supergenerics: Are They? 385
13.3.6 Complex Generics 386
13.4 Generics: Finished Products â" Role of Dissolution Testing 388
13.4.1 Tentative Approval to Final Approval: Setting QC Specifications! 388
13.4.2 Biowaivers: Global Considerations and Perspectives! 389
13.4.3 Regulatory Queries and Responses 392
13.5 Summary and Concluding Remarks 396
References 396
14 Successful Bioequivalence Investigations: Current Challenges and Possible Solutions! 400
14.1 Introduction and Objective(s) 400
14.2 Understanding Challenges and Approaches to Overcome Them! 402
14.2.1 Oral Dosage Forms 404
14.2.1.1 Highly Variable Drugs (HVDs) 405
14.2.1.2 Oral Dosage Forms: Locally Acting 406
14.2.2 Narrow Therapeutic Index (NTI) Drugs 409
14.2.3 Topical Dosage Forms 411
14.2.3.1 Ophthalmic Dosage Forms 413
14.2.4 Oral Inhalation Products 417
14.2.5 Complex Generics 420
14.2.6 Nutraceuticals and Natural Products 422
14.3 Concluding Remarks 423
References 424
15 Beyond Guidance(s): Convincing Regulatory Authorities Through Creative Dissolution Data Interpretation 434
15.1 Introduction and Objective(s) 434
15.2 Regulatory Guidance(s): Reading Versus Understanding! 435
15.3 Regulatory Submission: Premise and Expectation(s) 438
15.4 Handling Regulatory Query/Deficiency: Efficient and Satisfying Response 440
15.5 Winning an Argument: Three Cs to Succeed! 443
15.6 Sample Case Study(ies) 444
15.7 Summary and Concluding Remarks 447
References 447
16 Biosimilars: The Emerging Frontier for Generics â" Role of Dissolution Testing! 449
16.1 Introduction and Objective(s) 449
16.2 Generics, (Bio)betters, and Biosimilars: What Are They? 451
16.3 Regulatory Approval Process (Brief): Focus on Efficacy! 453
16.4 Role of Solubility and Dissolution 456
16.5 Concluding Remarks 458
References 459
17 Patentability of Drug Product Based on Dissolution Data: Intellectual Property Considerations! 461
17.1 Introduction and Objective(s) 461
17.2 Patentability and the Patent Process (Brief): Scientistâs Perspective 462
17.2.1 Is Solubility and Dissolution Patentable: Scientistâs Perspective 465
17.3 Pharmaceutical Product: Patentability and Role of Dissolution Testing 466
17.4 Patentability: Double-Edged Sword! 468
17.5 Concluding Remarks 471
References 471
18 Setting Up Clinical Therapeutics Safety-Based QC Specifications for Dissolution Testing of a Finished Product 473
18.1 Introduction and Objective(s) 473
18.2 Critical Quality Attributes (CQA): Role of In vitro Dissolution as a QC Test! 475
18.3 Clinical Drug Product Performance: Adequate or Predictable! 476
18.4 Clinically Relevant Specifications (CRS): Basics and Challenges! 478
18.4.1 Setting Up CRDS or CRS 481
18.5 Idealism and Pragmatism Versus Realism! 484
18.6 Concluding Remarks 489
References 490
19 Unlocking the Mystery(ies) While Predicting Bioavailability from Dissolution 493
19.1 Introduction and Objective(s) 493
19.2 The IVIVC Model and Objective(s) of IVIVC 494
19.3 Challenges Encountered in Predicting Bioavailability from Dissolution 495
19.4 What Are We Doing Now? 499
19.4.1 Mathematical Modeling: Limitations and Feel Good Phenomena! 499
19.4.2 BCS and Its Relation to Drug Formulationâs Dissolution Performance 500
19.4.3 The Application (or the Lack) of f 1 and f 2 Parameters 501
19.4.4 Dissolution Data Banks, Agency Recommendations, and Compendial Monographs 502
19.4.5 Dissolution Testing Apparatuses (Choice Versus Selection!) 503
19.4.6 Advent of Biophysiologically Relevant Dissolution Media(um) 504
19.4.7 What Are We Missing in This Picture? 505
19.5 What We Should Be Doing! The Way Forward: The Missing Link! 506
19.6 Advent of IVRT, IVPT, PBPK, and PBAM 508
19.6.1 Role of IVRT, IVPT, and PBAM in Predicting In Vivo Absorption of Drug from Oral Solid Dosage Forms 510
19.7 Summary and Concluding Remarks 511
References 512
Index 515
